CVS Replaces Lantus® With Basaglar®

It has been reported that U.S. pharmacy benefit manager CVS will drop Sanofi’s insulin drugs, Lantus® (insulin glargine injection, 100 units/ml) and Toujeo® (insulin glargine injection, 300 units/ml) from the list of medications for which it reimburses on behalf of health insurers.  In July CVS caremark® published a list of Formulary Drug Removals which indicates that in place of Lantus®, CVS will reimburse for Eli Lilly’s insulin glargine injection (100 units/ml), Basaglar®, and for Novo’s Levemir® (insulin detemir injection, 100 units/ml).  Basaglar® was approved in late 2016 and Levemir® was approved in 2005.